Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell, Cutaneous

Interventions

DRUG: RP6530

Sponsor

Rhizen Pharmaceuticals SA